MAL2 and meningioma: To further support our analysis, we examined a publicly available gene expression array data for meningiomas [7], and found significantly suppressed MAL2 gene expression in recurrent malignant samples compared to benign samples (P = 0.0096, two-tailed unpaired t-test).